{"filings":[{"id":105043,"accession_number":"0001193125-26-028333","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K/A","filed_at":"2026-01-29T23:59:59+00:00","items":["8.01","3.01"],"status":"ready","headline":"Synlogic confirms Nasdaq delisting, will trade on OTCQB as public shell","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Withdrew Nasdaq hearing on Jan 16, 2026; shares suspended Jan 21, 2026.","Believes it is a 'public shell' under Nasdaq rules post-delisting.","Applied for OTCQB Venture Market quotation; expects trading to begin soon.","Remains an SEC reporting company; business operations unaffected by transition.","No financial or operational changes announced; forward-looking statements caution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105044,"accession_number":"0001193125-26-016040","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Synlogic withdraws Nasdaq hearing; shares suspended Jan 21, will move to OTC Markets","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Synlogic withdrew its Nasdaq hearing request on Jan 16, 2026, after being deemed a public shell.","Nasdaq will suspend trading of SYBX common stock at open of business on January 21, 2026.","Company expects shares to be quoted on OTC Markets Group; remains an SEC reporting company.","Business operations expected unaffected by the delisting; no financial impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121289,"accession_number":"0001193125-25-319653","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Shareholders approve 2025 Equity Incentive Plan and reelect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 Plan approved: 1,000,000 new shares authorized, plus up to 332,468 from lapsing 2015 Plan awards.","Directors James Flynn and Richard P. Shea reelected as Class I directors with strong support.","Non-binding advisory vote on executive compensation approved (7.75M for, 17.5K against).","Ratification of KPMG as independent auditor for fiscal year 2025 (10.28M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121288,"accession_number":"0001193125-25-300824","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Synlogic it is a public shell; delisting possible unless hearing succeeds","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff believes Synlogic is a public shell, citing zero revenue, minimal R&D costs, and reduced operations since Feb 2024.","Notice received Nov 21, 2025; company disagrees and intends to request a hearing to contest the Staff's determination.","Hearing request automatically stays suspension/delisting pending outcome, but there is no assurance of a successful result.","Quarterly reports for nine months 2025 show no revenue and only $16,000 in R&D expenses, per the Staff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173845,"accession_number":"0000950170-25-024891","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synlogic Director Michael Heffernan Resigns from Board and Committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Heffernan resigned from the Synlogic board and its audit and nominating/governance committees on February 20, 2025.","The resignation was voluntary and not due to any disagreement with the company's operations, policies, or practices.","Heffernan's departure is effective immediately, reducing the board's committee membership.","Synlogic (SYBX) disclosed the change in a Form 8-K filed on February 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173844,"accession_number":"0000950170-25-005425","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synlogic board member Nick Leschly resigns effective Jan 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nick Leschly resigned from the Board and compensation committee on Jan 10, 2025.","Resignation was voluntary and not due to any disagreement with the company.","No replacement has been announced; board seat remains vacant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190823,"accession_number":"0000950170-24-139249","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synlogic CEO Antoine Awad leaves Dec 31; Mary Beth Dooley named new Principal Executive Officer and CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Antoine Awad's employment ends Dec 31, 2024; receives $218,856 lump-sum (6 months salary) plus $246,213 retention bonus.","Mary Beth Dooley, Head of Finance, appointed Principal Executive Officer and Principal Financial Officer effective Jan 1, 2025.","Dooley's base salary $325,000; 2024 target bonus 30% ($97,500); no bonus for 2025 or later.","Awad enters consulting agreement at $350/hour; equity grants extended and accelerated on change in control or dissolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190822,"accession_number":"0000950170-24-133381","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Synlogic stockholders reelect Nick Leschly as Class III director at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nick Leschly reelected as Class III director with 6,876,144 votes for and 317,492 withheld.","Non-binding advisory vote on executive compensation approved: 3,337,618 for, 543,326 against, 3,312,692 abstentions.","Ratification of KPMG as auditor for FY2024: 9,589,958 for, 43,758 against.","Quorum of 9,633,925 shares (82.36% of outstanding) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190821,"accession_number":"0000950170-24-125523","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic posts Q3 net loss of $0.1M, cash $19.4M; evaluating strategic options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $0.1M ($0.01 per share) vs $12.1M ($2.57 loss per share) in Q3 2023.","Cash and cash equivalents of $19.4M as of Sep 30, 2024; no revenue for Q3.","R&D expenses show $0.7M benefit due to clinical trial refund and accrual reversal.","Restructuring charges of $0.3M related to workforce reduction from Synpheny-3 discontinuation.","Retained Lucid Capital Markets to explore strategic alternatives including M&A or business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207295,"accession_number":"0000950170-24-093291","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic reports Q2 net income $2M on restructuring gain; exploring strategic options","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $20.0M as of June 30, 2024.","Net income $2.0M ($0.16/share) vs net loss $15.0M ($3.21/share) in Q2 2023; revenue zero.","R&D expenses fell to $2.2M from $11.8M YoY; restructuring gain of $3.8M from lease termination.","Retained Lucid Capital Markets to evaluate strategic alternatives including acquisition or merger.","In Feb 2024, discontinued pivotal PKU study (Synpheny-3) and reduced workforce."],"consensus_eps_estimate":-0.5202,"consensus_eps_actual":-2.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":8000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224705,"accession_number":"0000950170-24-059063","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic posts Q1 net loss of $31.6M; retains advisor to explore strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retained Lucid Capital Markets to evaluate acquisition, merger, or other strategic transaction.","Cash and short-term securities of $32.3M as of March 31, 2024.","Net loss of $31.6M ($2.60 per share) versus $15.6M ($3.39) in Q1 2023.","Restructuring charge of $28.2M related to discontinuation of Phase 3 PKU study of SYNB1934.","R&D expenses fell to $7.7M from $12.5M; G&A to $2.9M from $4.0M year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243969,"accession_number":"0000950170-24-034854","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synlogic appoints James Flynn to board; three directors resign same week","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Flynn appointed as Class I director effective March 19; he manages Nerium Capital, a healthcare-focused investment fund.","Flynn granted stock option for 4,000 shares and annual cash retainer of $40,000 (prorated).","Three directors resigned March 20: Mike Burgess, Lisa Kelly-Croswell, Patricia N. Hurter; none due to disagreement.","Resignations affect Audit, Compensation, Nominating & Governance, and Science & Technology committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243968,"accession_number":"0000950170-24-033145","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic discontinues PKU program; Q4 net loss $14.5M, cash $47.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Discontinued Synpheny-3 pivotal study of SYNB1934 for PKU; evaluating strategic options.","Q4 2023 revenue $2.8M (vs $0.1M prior year) from Roche collaboration.","Q4 net loss $14.5M ($1.71 per share) vs $16.7M ($3.54 per share) prior year.","Full year 2023 net loss $57.3M ($8.81 per share) vs $66.1M ($13.83) prior year.","Cash and equivalents $47.7M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243967,"accession_number":"0001193125-24-042887","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synlogic CEO Aoife Brennan to depart March 9; COO Antoine Awad to leave May 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Aoife Brennan's employment ends March 9, 2024; receives $628,305 severance (12 months base).","COO Antoine Awad's employment ends May 30, 2024; receives $218,856 severance (6 months base).","Both executives eligible for pro-rated 2024 bonuses: CEO $65,327, COO $87,302, at Company discretion.","Health insurance coverage extended: CEO up to 12 months, COO up to 6 months post-departure.","No replacement named for either role; transitions in progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243966,"accession_number":"0001193125-24-039969","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Synlogic adopts one-year poison pill after unsolicited share accumulation; hires Ladenburg for strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights plan triggered at 15% ownership (20% for passive institutional investors); expires Feb 20, 2025.","Ladenburg Thalmann engaged as financial advisor to assist with strategic review to maximize shareholder value.","Rights become exercisable at $12.00 per right; holders other than triggering party can buy shares at 50% discount.","Grandfathering for existing holders above threshold; rights redeemable for $0.001 before trigger.","Plan adopted following unsolicited stock accumulation by an unnamed investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243965,"accession_number":"0000950170-24-013803","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["2.02","2.05","5.02","8.01","9.01"],"status":"ready","headline":"Synlogic discontinues PKU study after data review; to cease operations, cut ~90% workforce, evaluate strategic options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Synpheny-3 study of SYNB1934 for PKU discontinued; internal data review found it unlikely to meet primary endpoint; safety acceptable.","Company will cease operations and explore strategic alternatives including acquisition, merger, reverse merger, sale of assets, or dissolution.","Workforce reduced by ~90%; CEO Aoife Brennan to depart March 9, 2024; estimated $6M in severance costs.","Cash, equivalents, and short-term investments at Dec 31, 2023: $47.7M (unaudited)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261384,"accession_number":"0000950170-23-073825","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Synlogic amends CEO and COO severance agreements, extending change-in-control benefits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Aoife Brennan's severance period extended from 12 to 18 months after a change-in-control termination.","COO Antoine Awad's severance period extended from 6 to 12 months after a change-in-control termination.","Both executives receive 100% target bonus lump sum, COBRA coverage up to 18/12 months, and accelerated equity vesting.","Amendments executed December 26, 2023, and filed as Exhibits 10.1 and 10.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261383,"accession_number":"0000950170-23-064783","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synlogic CFO Michael Jensen resigns effective Dec 1; receives $149K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michael Jensen resigned effective December 1, 2023; departure not due to any disagreement with the company.","Separation agreement includes a lump-sum payment of $149,178 in lieu of 2023 bonus.","Jensen is entitled to continued health insurance coverage for up to six months after departure.","He will assist with transition through the departure date; no replacement has been named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261382,"accession_number":"0000950170-23-063906","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synlogic reprices employee stock options to $1.85/share on Nov 10, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved one-time repricing on Nov 9, 2023; exercise price reduced to $1.85 (Nov 10 close).","Repricing covers all employee stock options (vested/unvested) under 2015 and 2017 equity plans; non-employee directors excluded.","CEO Aoife Brennan: 147,214 options repriced from weighted avg $51.78; CFO Michael Jensen: 35,330 from $19.78.","COO Antoine Awad: 52,693 options repriced from weighted avg $30.30.","Company expects no material impact on its statement of operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261381,"accession_number":"0000950170-23-061496","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic Q3 net loss narrows to $12.1M; cash runway extended into H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.1M ($2.57 per share) vs $17.9M ($3.73) in Q3 2022; revenue $0.4M from Roche collaboration.","Closed $21M underwritten public offering and earned $2.5M Roche milestone, extending cash runway into H1 2025.","Synpheny-3 pivotal trial in PKU on track: enrollment completion H2 2024, top-line data H1 2025.","FDA granted Fast Track Designation for labafenogene marselecobac (SYNB1934) for PKU.","Cash and investments $33.4M as of Sept 30, plus $19.6M net from October financing and $2.5M milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":602000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261380,"accession_number":"0000950170-23-059740","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Synlogic earns $2.5M milestone payment from Roche for IBD program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third milestone achieved under June 2021 Roche collaboration for Synthetic Biotic in IBD.","$2.5 million payment triggered; previous milestones in Sep 2021 and Aug 2022.","Roche retains exclusive option to license and commercialize the candidate.","Synlogic's Synthetic Biotics are oral, gut-restricted biotherapeutics for serious diseases.","Mylene Perreault, VP Research, emphasizes compelling fit with IBD disease biology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278625,"accession_number":"0001193125-23-246542","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Synlogic raises $21M in public offering, funds PKU Phase 3 and manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $21M from 7.39M shares and 7.39M warrants at $2.84 per unit.","Proceeds to fund Phase 3 SYNB1934 for PKU, BLA manufacturing, and SYNB1353 for HCU.","Top-line data for PKU Phase 3 Synpheny-3 study expected first half of 2025.","Existing cash plus offering expected to fund operations into first half of 2025.","Participants include New Enterprise Associates and a board member; Chardan underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278624,"accession_number":"0001193125-23-245646","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Synlogic implements 1-for-15 reverse stock split effective Sep 27, 2023 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:15 ratio effective 5:00 PM ET on Sep 27, 2023; shares outstanding reduce from ~69M to ~4.6M.","Split approved by shareholders at Sep 21 special meeting; no change in authorized shares, par value $0.001.","No fractional shares; cash in lieu based on Sep 27 closing price.","Stock continues on Nasdaq under symbol SYBX; new CUSIP 87166L209.","Primary goal: regain compliance with Nasdaq minimum $1.00 bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278623,"accession_number":"0001193125-23-240503","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Synlogic shareholders approve reverse stock split at 1:5 to 1:15 ratio","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved reverse stock split at ratio between 1:5 and 1:15; board to set final ratio.","46.38M votes for, 1.12M votes against, 0.74M abstained on reverse split proposal.","Adjournment proposal also approved with 47.23M votes for, 0.78M against.","~70.3% of eligible shares (48.24M of 68.60M) were present at the Sep 21, 2023 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278622,"accession_number":"0001193125-23-214303","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Synlogic and Roche amend collaboration; IBD option deadline extended to Jan 15, 2024 or later","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Roche holds exclusive option to negotiate a license for Synlogic's IBD Synthetic Biotic medicine.","Amendment extends option deadline to later of Jan 15, 2024 or 90 days after data delivery.","Original collaboration agreement effective June 16, 2021; amendment executed August 16, 2023.","Synlogic to deliver certain research data before the 90-day extension trigger.","No other changes to collaboration terms were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278621,"accession_number":"0000950170-23-040929","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic reports Q2 2023 net loss of $15.0M; Phase 3 PKU trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.0M ($0.21/sh) vs $15.8M ($0.22/sh) in Q2 2022; cash $46.3M.","Revenue $35K from Roche collaboration, down from $152K year-over-year.","R&D expenses $11.8M; G&A $3.9M, both slightly lower than prior year.","Initiated pivotal Phase 3 Synpheny-3 trial for labafenogene marselecobac (SYNB1934) in PKU (n=150).","FDA granted Fast Track designation; WHO approved INN 'labafenogene marselecobac'."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":209000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296841,"accession_number":"0001193125-23-167885","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Synlogic stockholders approve officer exculpation amendment, reelect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted to amend certificate of incorporation to permit officer exculpation for breach of fiduciary duty of care, effective June 15, 2023.","Four Class II directors reelected: Peter Barrett, Michael Heffernan, Lisa Kelly-Croswell, Edward Mathers.","Non-binding advisory vote on executive compensation passed with 48.3M for, 0.6M against, 0.2M abstain.","Ratification of KPMG as auditor for FY2023 approved with 59.1M for, 31.9k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296840,"accession_number":"0001193125-23-160355","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Synlogic initiates Phase 3 PKU study SYNB1934, cuts workforce 21%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated Synpheny-3 global pivotal Phase 3 trial of SYNB1934 for phenylketonuria (PKU), targeting ~150 patients.","Primary endpoint: change in plasma phenylalanine after 4-week placebo-controlled randomized withdrawal.","Workforce reduced by ~21%; expects $0.9M in severance costs in Q2/Q3 2023.","Cash runway extended into H2 2024 by prioritizing SYNB1934 and SYNB1353 programs.","Study design includes virtual/hybrid options; ages 18+ with potential expansion to 12+."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296839,"accession_number":"0000950170-23-020786","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic Q1 net loss $15.6M; cash $57.4M; PKU program gets FDA/EMA designations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.6M ($0.23 per share) vs $15.7M in Q1 2022; revenue flat at $0.2M.","Cash, equivalents and short-term investments $57.4M; runway into H2 2024.","FDA granted Rare Pediatric and Orphan Drug Designations for SYNB1934 in PKU; EMA also granted orphan designation.","Phase 3 trial (Synpheny-3) for SYNB1934 in PKU on track to start H1 2023.","SYNB1353 for HCU advancing to Phase 2; preclinical pipeline progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":174000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317205,"accession_number":"0000950170-23-010430","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic reports Q4 2022 net loss $16.7M; PKU Phase 3 on track for H1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $16.7M ($0.24/share) vs $15.1M ($0.21) in Q4 2021; full year net loss $66.1M ($0.92/share).","Cash, cash equivalents and marketable securities $77.6M; projected runway into H2 2024.","PKU program SYNB1934 on track for Phase 3 trial initiation in H1 2023; Rare Pediatric Disease Designation granted.","SYNB1353 for HCU received Rare Pediatric Disease Designation; proof of mechanism in Phase 1 study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317204,"accession_number":"0001193125-23-010643","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Synlogic receives FDA Rare Pediatric Disease Designation for SYNB1934 in PKU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted RPDD for SYNB1934, a synthetic biotic candidate for phenylketonuria (PKU).","Company plans to start Synpheny-3 pivotal Phase 3 study for SYNB1934 in H1 2023.","Follows similar RPDD for SYNB1353 for homocystinuria (HCU) received in December 2022.","Designation highlights the urgent need for new PKU treatment options in children."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335479,"accession_number":"0001193125-22-305412","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Synlogic reports SYNB8802 Phase 1b proof of concept: -38% urinary oxalate reduction in enteric hyperoxaluria","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SYNB8802 reduced urinary oxalate by 38% vs placebo at 3x10^11 TID dose in Roux-en-Y gastric bypass patients.","No serious adverse events; GI AEs mild and similar in frequency between active and placebo groups.","Third positive clinical readout for Synlogic in 2022, following SYNB1934 for PKU and SYNB1353 for homocystinuria.","Company to host webcast today at 8:30 AM ET with Dr. Kyle Wood of UAB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335478,"accession_number":"0001193125-22-301870","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Synlogic receives Nasdaq delisting notice over sub-$1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Synlogic on Dec 6, 2022, that bid price was below $1.00 for 30 consecutive business days.","Company has 180-day grace period until June 5, 2023, to regain compliance.","To comply, bid price must close at $1.00 or higher for at least 10 consecutive business days.","Failure to regain compliance by deadline may lead to delisting; company can appeal.","Synlogic is considering alternatives, including a potential reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335477,"accession_number":"0001193125-22-295406","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-11-30T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Synlogic: SYNB1353 achieves proof of mechanism in HCU; cuts workforce 25%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SYNB1353 reduced plasma methionine AUC by -24.8% and -26.2% at 1x10^12 dose vs placebo -2.1% in Phase 1.","FDA granted Orphan Drug Designation to SYNB1353 for homocystinuria, offering market exclusivity potential.","Workforce reduced by ~25% to extend cash runway into H2 2024; severance costs estimated at $0.8M.","Proof-of-concept data for SYNB8802 in enteric hyperoxaluria expected in Q4 2022.","Phase 3 pivotal study of SYNB1934 for PKU on track to initiate in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335476,"accession_number":"0000950170-22-025640","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Synlogic extends cleanroom agreement with Azzur through Dec 2023 for $1.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Synlogic OpCo entered SOW extending Azzur Suite access from Apr 2023 to Dec 2023.","Two additional extension options available: to Jun 2024 and Dec 2024.","Total estimated cost during the 9-month term is $1.7 million.","The SOW supersedes previous 14-month SOW that ended March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335475,"accession_number":"0000950170-22-024119","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic Q3 net loss $17.9M; cash $91.7M; positive Phase 2 PKU data supports Phase 3 start in H1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments of $91.7M as of Sept 30, 2022; runway into 2024.","Q3 revenue $0.7M (vs $0.9M Q3 2021) from Roche IBD collaboration; net loss $17.9M ($0.25/sh) vs $16.0M ($0.29/sh) prior year.","R&D expense $14.6M, G&A $4.4M, both up from prior year period.","Positive Phase 2 'Synpheny-1' top-line data for SYNB1934/SYNB1618 in PKU; Phase 3 registrational study planned H1 2023.","Earned research milestone from Roche collaboration for IBD Synthetic Biotic candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":1074000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335474,"accession_number":"0001193125-22-264177","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-10-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Synlogic reports positive Phase 2 PKU data; SYNB1934 advances to Phase 3 in H1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 Synpheny-1 study met primary endpoint: 60% response rate with 42% mean Phe reduction among responders.","SYNB1934 showed -34% mean change from baseline in fasting plasma Phe; SYNB1618 showed -20%.","All adverse events mild/moderate, primarily GI; no serious adverse events; 3 discontinuations due to GI AEs.","Company confirms SYNB1934 as Phase 3 candidate; pivotal study expected to begin H1 2023.","Data from 20 adult PKU patients; results consistent with adjunctive use with sapropterin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352904,"accession_number":"0001193125-22-238450","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-09-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Synlogic achieves second research milestone under Roche IBD collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second pre-specified milestone earned; milestone payment triggered under Roche collaboration.","First milestone was achieved and payment earned in September 2021.","Collaboration Agreement signed June 2021; Roche has exclusive option to negotiate a license after research period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352903,"accession_number":"0000950170-22-016625","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic Q2 2022 net loss $15.8M; cash $106.8M funds into 2024; three data readouts in H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.8M ($0.22 per share) vs $14.5M ($0.28) in Q2 2021; revenue $0.2M from Roche IBD collaboration.","Cash, equivalents, and short-term investments $106.8M as of June 30, 2022; projected runway into 2024.","Plan to report Phase 2 PKU data in H2 2022 and start Phase 3 in H1 2023; HCU Phase 1 and EH proof-of-concept data also due H2 2022.","Named SYNB2081 (uric acid-lowering Synthetic Biotic for gout), second candidate from Ginkgo Bioworks partnership.","R&D expenses $12.1M (up from $10.7M) and G&A $4.1M (flat YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":396000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370515,"accession_number":"0001193125-22-172896","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Synlogic stockholders reelect three Class I directors, approve advisory vote on exec compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class I directors reelected: Aoife Brennan, Patricia Hurter, Richard P. Shea; each received over 43.8M votes for.","Non-binding advisory vote on named executive officer compensation passed with 47.97M for, 667.7K against, 156.2K abstain.","Ratification of KPMG as independent auditor for FY2022 approved: 58.92M for, 69.8K against, 45.8K abstain.","Annual meeting quorum: 59.03M shares (84% of outstanding) present or represented by proxy on June 9, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370514,"accession_number":"0001193125-22-148082","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic reports Q1 net loss of $15.7M; cash $120.5M supports runway into 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.7M ($0.22/share) vs $15.0M ($0.36/share) in Q1 2021.","Revenue of $0.2M from Roche collaboration; no revenue in Q1 2021.","Cash, cash equivalents and short-term investments $120.5M; expected funding into 2024.","PKU program progressing to Phase 3 readiness; expects Phase 2 data and candidate selection in H2 2022.","Michael Jensen appointed CFO in March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":244000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389591,"accession_number":"0001193125-22-077895","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic Q4 2021 net loss $15.1M; cash $136.6M; PKU Phase 3 on track for H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net loss $15.1M ($0.21/share) vs $14.6M ($0.39/share) in Q4 2020; FY 2021 net loss $60.6M ($1.09/share).","Cash, equivalents & marketable securities $136.6M at Dec 31, 2021; projected runway into 2024.","PKU program: Phase 2 SynPheny-1 data expected H1 2022; Phase 3 trial initiation planned H2 2022.","Appointed Michael Jensen as CFO in March 2022; he was formerly CFO of Intrinsic Therapeutics.","HCU candidate SYNB1353 IND submission and Phase 1 healthy volunteer data expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389590,"accession_number":"0001193125-22-064445","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Synlogic appoints Michael Jensen as CFO effective March 3, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Jensen named CFO; previously CFO at Intrinsic Therapeutics and Taconic Biosciences.","Base salary $395K, bonus target 40%, option grant of 230K shares at $2.23, 30K RSUs.","Employment agreement provides 6-month severance upon termination without cause or for good reason.","Press release notes Synlogic on track to start Phase 3 study for PKU in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389589,"accession_number":"0001193125-22-016046","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2022-01-24T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Synlogic extends Azzur cleanroom lease through Mar 2023; adds $650k upgrade","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First SOW commits $650,000 to renovate Azzur's cleanroom in Waltham, MA for expanded use.","Second SOW replaces prior SOW, extending access term from Dec 2022 to Mar 2023.","Total estimated project cost for the Term (access, upgrade, support) is $2.4 million.","Agreements are under the existing License and Services Agreement with Azzur dated April 28, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407544,"accession_number":"0001193125-21-325370","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic reports Q3 net loss $16M; PKU Phase 2 shows proof of concept, moving to Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Interim Phase 2 SynPheny-1 data: SYNB1618 achieved proof of concept with statistically significant Phe reduction in PKU patients.","SYNB1934 showed 2x improvement in Phe metabolism biomarkers vs SYNB1618; Phase 3 start planned in 2022.","Cash, equivalents and short-term investments $150.1M as of Sept 30, 2021; net proceeds $48.4M from public offering.","Revenue $0.9M from Roche IBD collaboration; first milestone payment earned; no further SYNB1891 studies planned.","Net loss $16.0M ($0.29/share) vs $13.2M ($0.36/share) in Q3 2020; R&D expense $13.4M, G&A $3.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":1162000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407543,"accession_number":"0001193125-21-323850","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Synlogic and Ginkgo announce clinical candidate SYNB1353 for homocystinuria; IND filing expected 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SYNB1353 is an investigational Synthetic Biotic medicine for homocystinuria (HCU), developed using Synlogic's platform and Ginkgo's codebase.","First candidate from Synlogic-Ginkgo collaboration to enter IND-enabling studies.","Synlogic expects to file an IND with FDA and begin clinical development in 2022.","Preclinical data to be presented at International Congress of Inborn Errors of Metabolism 2021 (Nov 21-23)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426565,"accession_number":"0001193125-21-280730","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2021-09-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Synlogic prices $45M public offering of 15M shares at $3.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 15 million shares of common stock at $3.00 per share.","Gross proceeds expected to be $45 million; net proceeds of approximately $42.3 million after discounts.","Underwriters granted 30-day option to purchase up to an additional 2.25 million shares.","Offering expected to close on or about September 27, 2021, subject to customary closing conditions.","Jefferies and SVB Leerink are acting as joint book-running managers; Chardan as lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426564,"accession_number":"0001193125-21-276762","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2021-09-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Synlogic reports positive PKU data: SYNB1618 reduces Phe, SYNB1934 shows 2x activity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SYNB1618 showed 20% reduction in fasting plasma Phe after 14 days at 1e12 dose in Phase 2 SynPheny-1 interim analysis.","SYNB1934 demonstrated two-fold higher activity than SYNB1618 in head-to-head Phase 1 study based on biomarkers of Phe metabolism.","Safety profile consistent with prior studies: no serious AEs, no drug-related discontinuations; AEs mild-moderate GI.","Company plans to complete Phase 2 SynPheny-1 with SYNB1934 arm and prepare Phase 3 program for most promising strain in 2022.","Shares trade on Nasdaq under SYBX; data support Synthetic Biotic platform for metabolic diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426563,"accession_number":"0001193125-21-244019","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Synlogic Q2 2021 net loss narrows to $14.5M; PKU and Enteric Hyperoxaluria trials on track for 2H readouts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments of $115.5M as of June 30, 2021; runway into second half of 2023.","Net loss of $14.5M ($0.28/shr) vs. $15.5M ($0.44/shr) in Q2 2020; revenue of $0.2M from Roche IBD collaboration.","SYNB1618 Phase 2 PKU trial ongoing; Phase 1 of next-generation SYNB1934 initiated in July 2021.","SYNB8802 Enteric Hyperoxaluria Part B enrolling; proof-of-concept data expected in 2H 2021.","Combination arm of SYNB1891 (atezolizumab) Phase 1 in solid tumors; mature data expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":246000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426562,"accession_number":"0001193125-21-231447","cik":1527599,"company_name":"SYNLOGIC, INC.","ticker":"SYBX","form_type":"8-K","filed_at":"2021-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synlogic CMO Richard Riese resigns voluntarily on July 29, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Richard Riese, M.D., Ph.D., resigned on July 29, 2021.","Resignation was voluntary and not due to any disagreement with Synlogic.","No successor or transition details were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7719783.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-07-30T23:59:59+00:00|426562"}